Further, BRAF mutations were identified in 6 samples (pediatric n = 2, adult n = 4), including BRAF V600E (n = 2) and other kinase activating mutations, which are commonly seen in melanomas and histiocytic disorders and been highly amenable to BRAF-inhibitor therapy [14, 15]. Here, BRAF is linked to melanoma.